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Summary
This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule
in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were
enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered
by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only
3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The
fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is
well tolerated but has no activity in advanced renal cell carcinoma.
Introduction
Metastatic renal cell carcinoma remains a highly lethal
disease with five-year survival ranging from 0 to 10%
[1]. Therapeutic options are limited with minimal
activity of hormonal and chemotherapeutic agents in
advanced disease [2]. Biological response modifiers
such as interleukin-2 and interferon can induce partial
and complete responses in small numbers of patients,
however a recent phase III trial demonstrated dis-
appointing response rates of only 7.5 and 6.5% for
interferon alfa-2a and interleukin-2, respectively [3].
Suramin is a polysulfonated naphthlyurea which
has been used as an antiparasitic agent for 70 years
[4]. It has been investigated as an antiviral agent in ac-
quired immunodeficiency syndrome and as an antineo-
plastic agent in various solid tumors and hematologic
neoplasms [5].
Suramin appears to have a narrow therapeutic
range, is extensively protein bound, and has a plasma
terminal half-life greater than 50 days. As a con-
sequence, when administered by continuous infusion
significant dose-limiting toxicities, including coagu-
lopathy and polyradiculopathy, were observed [6].
Eisenberger and colleagues have demonstrated the
feasibility of administering suramin in short inter-
mittent bolus injections using adaptive control with
feedback to adjust plasma drug concentrations [7].
Subsequent observations showed there was little in-
terpatient variability in pharmacokinetic parameters,
which led to a fixed schedule designed to maintain
plasma concentrations in the 150–250µg/ml range
[8].
Two previous trials of suramin in metastatic renal
cell carcinoma have been performed. La Rocca et
al. treated 12 patients with metastatic disease with
suramin administered by continuous infusion with
serial monitoring of plasma suramin levels. There
were no objective responses and toxicity included vor-
tex keratopathy and renal insufficiency [9]. Motzer
and colleagues treated 26 patients with advanced
renal cell carcinoma with suramin administered as
a daily continuous infusion of 350 mg/m2 to a tar-
get serum plasma concentration of 280–300µg/ml.
One patient had a partial response and toxicity in-
cluded immune-mediated thrombocytopenia and sta-
phylococcus sepsis not associated with neutropenia
[10]. Both of these trials enrolled a subset of patients
who had received prior immunotherapy or chemother-
apy.
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Using the recently developed fixed dose schedule
of suramin we performed a phase II trial in previously
untreated patients with advanced renal cell carcinoma.
Methods
Study design Eligible patients had histologically
confirmed renal cell carcinoma and evidence of pro-
gressive, bidimensionally measurable metastatic dis-
ease. Patients must have been disease-free from prior
malignancies for at least 5 years, with an Eastern
Cooperative Oncology Group (ECOG) performance
status of 0 or 1 at entry. Patients must not have received
prior biological response modifiers or chemotherapy.
Prior hormonal therapy was allowed as was radio-
therapy if there was documented disease progression
within the radiation field (if the only site of measur-
able disease was within the radiation portal). Patients
could not be receiving anticoagulant therapy and pa-
tients with brain metastases were excluded. Adequate
renal, hepatic, metabolic and bone marrow function
was required as manifested by a serum creatinine
≤ 1.5 mg/dl, aspartate aminotransferase (AST)< 2.5
times the upper limit of normal, normal prothom-
bin time (PT) and partial thromboplastin time (PTT),
serum calcium≤ 10.5 mg/dl and a granulocyte count
≥ 1,500/µL and platelet count≥ 100,000/µL. Written
informed consent was obtained from all patients.
Therapy Suramin was provided by the Division of
Cancer Treatment, National Cancer Institute. One-
gram aliquots were reconstituted with 10 ml of sterile
water for injection (USP), to yield a 10% (100 mg/ml)
solution. Suramin was diluted for infusion in 500 ml
of normal saline (USP). The initial dose (day 1) was
divided into a test dose of 200 mg administered in-
travenously (IV) over a 2-hour period. Suramin was
administered as a 1-hour IV infusion according to the
schedule listed in Table 1. All patients were treated
with hydrocortisone 20 mg orally in the morning and
afternoon starting with day 1 of therapy. Therapy was
held for grade 3 and 4 toxicity (NCI common toxicity
criteria) and resumed at the point in the treatment cycle
that therapy was held irrespective of the period of
treatment delay. Therapy was continued for 12 weeks
or until disease progression. Responding patients were
eligible for a second 12-week cycle of therapy.
Baseline data Prior to study entry all patients under-
went a physical examination, and ECOG performance
Table 1. Suramin dosing schedule



















status and weight were recorded. Pre-therapy determ-
inations were made of hemoglobin level, leukocyte
count with differential, platelet count, serum levels of
electrolytes, creatinine, calcium, PT and PTT. With
the exception of the serum calcium all these studies
were repeated on a weekly basis during therapy.
Suramin was held for grade 2 or greater neuro-
pathy, creatinine values> 2.9 mg/dl, grade 3 or
greater coagulopathy, neutrophil counts< 1500/µL
and platelet count< 100,000/µL. In addition therapy
was held for unexpected grade 2 or greater toxicity
and was discontinued if vortex keratopathy developed.
Tumor measurements were repeated at week 14 of
study. A complete response (CR) was defined as
the complete disappearance of all clinical detectable
disease measured by physical examination and/or ra-
diographic studies for a period of at least 4 weeks.
Categorization as a partial response (PR) required a
≥ 50% decrease in the sum of the products of the
2 longest perpendicular dimensions of all measurable
lesions for a period of at least 4 weeks without an
increase in the size of any area known to contain ma-
lignant disease and without the appearance of any new
areas of disease. Progressive disease (PD) was defined
as an increase of at least 25% in the size of measurable
lesions or the development of any new lesions.
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Table 2. Patient characteristics
Characteristic No. of patients (%)
Age (yrs)
Median (range) 58 (38–73)
Female 4 (29)
Performance status
Median (range) 1 (0–1)









From November 1994 through December 1997, 14 pa-
tients were entered into this trial and all were evaluable
for toxicity. One patient developed grade 4 hypergly-
cemia and was removed from study at week 3 without
reevaluation of disease status.
Clinical characteristics and treatmentPatient char-
acteristics are listed in Table 2. The median age was 58
(range, 38–73 years) and the majority of patients (pts)
were male. Eight patients presented with synchronous
metastases, 6 having had prior nephrectomy. Eight pa-
tients had multiple sites of metastatic disease. Three
patients completed the 12-week course of suramin.
The median number of doses administered (18 max-
imum) was 12 (range 7–18). Treatment delays were
required in 6 patients secondary to neutropenia (2 pts),
thrombocytopenia (1 pt), nausea and vomiting (1 pt),
grade 2 AST (1 pt), grade 2 lipase (1 pt), and patient
choice (1 pt).
Toxicity There were no treatment-related deaths.
Therapy was generally well tolerated. No patient de-
veloped neurotoxicity or vortex keratopathy. Eleven
patients developed a characteristic, transient grade 1–2
rash. All patients developed grade 1–2 fatigue. Grade
3 and 4 toxicities included diarrhea (G3, 1 pt), anemia
(G3, 1 pt), neutropenia (G3, 1 pt; G4, 1 pt), metabolic
(hyperglycemia G4, 1 pt), and pulmonary (dyspnea
G3, 1 pt).
Response Thirteen patients were evaluable for re-
sponse. One patient developed grade 4 hyperglycemia
during week three of therapy and went off study,
without reevaluation of disease status. One patient had
stable disease following completion of therapy, and
the other 12 patients had disease progression either
during therapy (10 pts) or at the completion of protocol
therapy (2 pts).
Discussion
Metastatic renal cell carcinoma remains a major di-
lemma to clinical oncologists. It is a disease whose
natural history is typically aggressive and rapidly pro-
gressive but alternatively may have a more protracted
course. This biological diversity is illustrated by the
6.6% response rate (including 3% complete respon-
ders) in the placebo arm of a recently completed phase
III trial of gamma interferon in advanced renal cell
carcinoma [11].
In the decade of the 1990s the biological response
modifiers interleukin-2 (IL-2) and interferon alfa have
become the primary therapies used to treat metastatic
renal cell carcinoma. The optimal dose and sched-
ules of these agents remains undefined, and the role
of combination therapy with or without chemotherapy
is uncertain. A recently reported large, phase III trial
compared IL-2 administered intravenously at a dose
of 18× 106 IU per square meter, with interferon alfa-
2a administered subcutaneously at a dose of 18× 106
and with a combination of IL-2 and interferon alfa-2a
[3]. Overall response rates were 6.5, 7.5 and 18.6%,
respectively. Although a higher response rate to the
IL-2 and interferon combination was observed there
were no differences in overall survival and not sur-
prisingly, the toxicity of the IL-2 plus alfa interferon
combination arm was significant.
Suramin has documented activity in hormone-
refractory metastatic prostate cancer. A recently com-
pleted phase III trial randomized 478 opiate-requiring
advanced prostate cancer patients to receive either
suramin (treated with the same fixed dosage sched-
ule as used in this phase II trial) with hydrocortisone
versushydrocortisone alone. Although there was no
improvement in overall survival, patients treated with
suramin plus hydrocortisone demonstrated a statistic-
ally significant palliative response and delay in disease
progression [5].
The mechanism of suramin’s antineoplastic activ-
ity is unknown. Suramin is known to impact on
186
numerous growth regulatory systems including the
inhibition of viral reverse transcriptase, inhibition
of various growth factors including basic fibroblast
growth factor, epidermal growth factor, insulin growth
factor and many others [10]. The two previous clin-
ical trials of suramin in advanced renal cell carcinoma
were designed based on the rationale that renal cell
carcinoma demonstrates altered expression of growth
factors, making suramin an agent of potential interest
[9,10].
This study was designed to assess the efficacy of
suramin given on a fixed dose schedule in patients
previously untreated for metastatic disease. The fixed
dosage schedule utilized in this trial was well toler-
ated. We observed the characteristic “suramin rash”
in the majority of patients, along with mild peripheral
edema and progressive fatigue. These findings were
consistent with the recently reported phase III trial [5].
Suramin, when administered using this fixed dose
schedule, demonstrated essentially no activity in ad-
vanced renal cell carcinoma. We believe that further
studies of suramin in advanced renal cell carcinoma
are not warranted.
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